Table 3.
Open in new tab

Cox regression analyses for the determinants of recurrence of MPGN (54 events)

Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).09
 <301.00 (reference)
 30–600.81 (0.33–2.01)
 >601.98 (0.61–6.49)
Gender.75
 Female1.00 (reference)
 Male0.89 (0.46–1.75)
Time to kidney failure on native kidneys (months).35
 ≤541.00 (reference)
 >540.75 (0.41–1.38)
Type of MPGN
Immune complex mediated
1.00 (reference)		<.001

1.00 (reference)		<.001
Complement mediated4.47 (2.39–8.32)5.32 (2.88–9.43)
Transplantation decade.546
 1981–19901.00 (reference)
 1991–20001.04 (0.24–4.59)
 2001–20101.77 (0.38–8.19)
 2011–20211.32 (0.23–7.54)
Type of donor.92
 Cadaveric1.00 (reference)
 DCD0.93 (0.25–3.44)
 Living donor1.76 (0.36–8.66)
 Living-related donor0.98 (0.12–5.42)
Cold ischaemia time (hours).28
 ≤171.00 (reference)
 >171.42 (0.76–2.66)
HLA-A/B/DR mismatch.83
 ≤31.00 (reference)
 >31.07 (0.56–2.05)
Induction therapy.59
 No1.00 (reference)
 Yes1.04 (0.89–1.21)
Maintenance treatment with CS + Tac + MMF.11
 No1.00 (reference)
 Yes1.92 (0.87–4.23)
Immediate graft function
No
1.00 (reference)
.18
 Yes1.62 (0.79–3.32)
Post-transplant eGFR (mL/min/1.73 m2).69
 ≤551.00 (reference)
 >550.87 (0.43–1.74)
Rejection episode during follow-up.55
 No1.00 (reference)
 Yes0.77 (0.33–1.82)
Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).09
 <301.00 (reference)
 30–600.81 (0.33–2.01)
 >601.98 (0.61–6.49)
Gender.75
 Female1.00 (reference)
 Male0.89 (0.46–1.75)
Time to kidney failure on native kidneys (months).35
 ≤541.00 (reference)
 >540.75 (0.41–1.38)
Type of MPGN
Immune complex mediated
1.00 (reference)		<.001

1.00 (reference)		<.001
Complement mediated4.47 (2.39–8.32)5.32 (2.88–9.43)
Transplantation decade.546
 1981–19901.00 (reference)
 1991–20001.04 (0.24–4.59)
 2001–20101.77 (0.38–8.19)
 2011–20211.32 (0.23–7.54)
Type of donor.92
 Cadaveric1.00 (reference)
 DCD0.93 (0.25–3.44)
 Living donor1.76 (0.36–8.66)
 Living-related donor0.98 (0.12–5.42)
Cold ischaemia time (hours).28
 ≤171.00 (reference)
 >171.42 (0.76–2.66)
HLA-A/B/DR mismatch.83
 ≤31.00 (reference)
 >31.07 (0.56–2.05)
Induction therapy.59
 No1.00 (reference)
 Yes1.04 (0.89–1.21)
Maintenance treatment with CS + Tac + MMF.11
 No1.00 (reference)
 Yes1.92 (0.87–4.23)
Immediate graft function
No
1.00 (reference)
.18
 Yes1.62 (0.79–3.32)
Post-transplant eGFR (mL/min/1.73 m2).69
 ≤551.00 (reference)
 >550.87 (0.43–1.74)
Rejection episode during follow-up.55
 No1.00 (reference)
 Yes0.77 (0.33–1.82)

Significant values in bold.

CS, corticosteroids; DCD, donation after circulatory death; MMF, mycophenolate mofetil; Tac, tacrolimus.

Table 3.
Open in new tab

Cox regression analyses for the determinants of recurrence of MPGN (54 events)

Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).09
 <301.00 (reference)
 30–600.81 (0.33–2.01)
 >601.98 (0.61–6.49)
Gender.75
 Female1.00 (reference)
 Male0.89 (0.46–1.75)
Time to kidney failure on native kidneys (months).35
 ≤541.00 (reference)
 >540.75 (0.41–1.38)
Type of MPGN
Immune complex mediated
1.00 (reference)		<.001

1.00 (reference)		<.001
Complement mediated4.47 (2.39–8.32)5.32 (2.88–9.43)
Transplantation decade.546
 1981–19901.00 (reference)
 1991–20001.04 (0.24–4.59)
 2001–20101.77 (0.38–8.19)
 2011–20211.32 (0.23–7.54)
Type of donor.92
 Cadaveric1.00 (reference)
 DCD0.93 (0.25–3.44)
 Living donor1.76 (0.36–8.66)
 Living-related donor0.98 (0.12–5.42)
Cold ischaemia time (hours).28
 ≤171.00 (reference)
 >171.42 (0.76–2.66)
HLA-A/B/DR mismatch.83
 ≤31.00 (reference)
 >31.07 (0.56–2.05)
Induction therapy.59
 No1.00 (reference)
 Yes1.04 (0.89–1.21)
Maintenance treatment with CS + Tac + MMF.11
 No1.00 (reference)
 Yes1.92 (0.87–4.23)
Immediate graft function
No
1.00 (reference)
.18
 Yes1.62 (0.79–3.32)
Post-transplant eGFR (mL/min/1.73 m2).69
 ≤551.00 (reference)
 >550.87 (0.43–1.74)
Rejection episode during follow-up.55
 No1.00 (reference)
 Yes0.77 (0.33–1.82)
Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).09
 <301.00 (reference)
 30–600.81 (0.33–2.01)
 >601.98 (0.61–6.49)
Gender.75
 Female1.00 (reference)
 Male0.89 (0.46–1.75)
Time to kidney failure on native kidneys (months).35
 ≤541.00 (reference)
 >540.75 (0.41–1.38)
Type of MPGN
Immune complex mediated
1.00 (reference)		<.001

1.00 (reference)		<.001
Complement mediated4.47 (2.39–8.32)5.32 (2.88–9.43)
Transplantation decade.546
 1981–19901.00 (reference)
 1991–20001.04 (0.24–4.59)
 2001–20101.77 (0.38–8.19)
 2011–20211.32 (0.23–7.54)
Type of donor.92
 Cadaveric1.00 (reference)
 DCD0.93 (0.25–3.44)
 Living donor1.76 (0.36–8.66)
 Living-related donor0.98 (0.12–5.42)
Cold ischaemia time (hours).28
 ≤171.00 (reference)
 >171.42 (0.76–2.66)
HLA-A/B/DR mismatch.83
 ≤31.00 (reference)
 >31.07 (0.56–2.05)
Induction therapy.59
 No1.00 (reference)
 Yes1.04 (0.89–1.21)
Maintenance treatment with CS + Tac + MMF.11
 No1.00 (reference)
 Yes1.92 (0.87–4.23)
Immediate graft function
No
1.00 (reference)
.18
 Yes1.62 (0.79–3.32)
Post-transplant eGFR (mL/min/1.73 m2).69
 ≤551.00 (reference)
 >550.87 (0.43–1.74)
Rejection episode during follow-up.55
 No1.00 (reference)
 Yes0.77 (0.33–1.82)

Significant values in bold.

CS, corticosteroids; DCD, donation after circulatory death; MMF, mycophenolate mofetil; Tac, tacrolimus.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close